Parisa Lotfinejad 个人学术档案

引用次数

	总计	2019 年至今
引用	649	581
h 指数	12	12
i10 指数	14	13

180

135

2014201520162017201820192020202120222023202411 16 20 10 9 10 12 88 178 178 114

合著作者

behzad baradaranImmunology Research Center, Tabriz University of Medical Sciences在 tbzmed.ac.ir 的电子邮件经过验证
prof. Nicola Silvestris - Full Professor i...Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Italy在 unime.it 的电子邮件经过验证
Tohid KazemiTabriz University of Medical Sciences在 tbzmed.ac.ir 的电子邮件经过验证
Mohammad Amini DavoudlouJohn Curtin School of Medical Research, Australian National University在 anu.edu.au 的电子邮件经过验证
Elmira Roshani AslAssistant Professor of clinical Biochemistery School of Nursing and Midwifery Saveh University of在 savehums.ac.ir 的电子邮件经过验证
Amir Ali MokhtarzadehAssistant Professor of Pharmaceutical Biotechnology,Tabriz University of Medical Sciences在 tbzmed.ac.ir 的电子邮件经过验证
Afshin DerakhshaniUniversity of Calgary在 ucalgary.ca 的电子邮件经过验证
Zahra AsadzadehImmunology Research Center,Tabriz University of Medical Sciences, Tabriz, Iran在 tbzmed.ac.ir 的电子邮件经过验证
Mohammad Asghari JafarabadiBiostatistician, Cabrini-Monash University在 monash.edu 的电子邮件经过验证
Souzan NajafiImmunology Research Center, Tabriz University of Medical Sciences在 tbzmed.ac.ir 的电子邮件经过验证
siamak sandoghchian shotorbaniAssociate Prof, Tabriz university of medical siences在 tbzmed.ac.ir 的电子邮件经过验证
Reza SafaralizadehProfessor of Molecular Genetics, University of Tabriz, Iran在 tabrizu.ac.ir 的电子邮件经过验证
Nima HemmatPeter MacCallum Cancer Centre, University of Melbourne在 petermac.org 的电子邮件经过验证
Amir BaghbanzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran在 tbzmed.ac.ir 的电子邮件经过验证
Narges DastmalchiUniversity of Tabriz在 tabrizu.ac.ir 的电子邮件经过验证
Elham BaghbaniImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran在 tbzmed.ac.ir 的电子邮件经过验证
Nafiseh VahedResearch Center for Evidence Based Medicine, Tabriz University of Medical Sciences在 tbzmed.ac.ir 的电子邮件经过验证
Fariba PashazadehPhD Student of Epidemiology, Research Center for Evidence-Based Medicine, Tabriz Universi在 tbzmed.ac.ir 的电子邮件经过验证
Negar HosseinkhaniDepartment of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences在 tbzmed.ac.ir 的电子邮件经过验证
Naime Majidi ZolbaninAssistant Professor of Pharmacology, Urmia University of Medical Sciences在 umsu.ac.ir 的电子邮件经过验证

关注

Parisa Lotfinejad

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

在 pitt.edu 的电子邮件经过验证

Immunology cancer Immunotherapy Targeted Therapy R programming


标题按引用次数排序按年份排序按标题排序	引用次数引用次数	年份
Interplay between MAPK/ERK signaling pathway and MicroRNAs: A crucial mechanism regulating cancer cell metabolism and tumor progression ER Asl, M Amini, S Najafi, B Mansoori, A Mokhtarzadeh, A Mohammadi, ... Life sciences 278, 119499, 2021	123	2021
Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy P Lotfinegad, A Movassaghpour, J Majidi, B Baradaran Advanced pharmaceutical bulletin 4 (1), 5, 2014	83	2014
Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): a … P Lotfinejad, M Asghari Jafarabadi, M Abdoli Shadbad, T Kazemi, ... Diagnostics 10 (9), 704, 2020	79	2020
Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope C Aslan, SH Kiaie, NM Zolbanin, P Lotfinejad, R Ramezani, F Kashanchi, ... BMC biotechnology 21, 1-12, 2021	71	2021
Antioxidants with two faces toward cancer N Dastmalchi, B Baradaran, S Latifi-Navid, R Safaralizadeh, ... Life Sciences 258, 118186, 2020	50	2020
A systematic review on the therapeutic potentiality of PD-L1-inhibiting microRNAs for triple-negative breast cancer: Toward single-cell sequencing-guided biomimetic delivery MA Shadbad, S Safaei, O Brunetti, A Derakhshani, P Lotfinejad, ... Genes 12 (8), 1206, 2021	38	2021
The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers O Kooshkaki, A Derakhshani, H Safarpour, S Najafi, P Vahedi, O Brunetti, ... International journal of molecular sciences 21 (14), 5034, 2020	37	2020
PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines P Lotfinejad, T Kazemi, S Safaei, M Amini, E Baghbani, SS Shotorbani, ... Biomedicine & Pharmacotherapy 138, 111436, 2021	35	2021
PD-1/PD-L1 axis importance and tumor microenvironment immune cells P Lotfinejad, T Kazemi, A Mokhtarzadeh, D Shanehbandi, FJ Niaragh, ... Life Sciences 259, 118297, 2020	35	2020
A systematic review and meta-analysis on the significance of TIGIT in solid cancers: Dual TIGIT/PD-1 blockade to overcome immune-resistance in solid cancers N Hosseinkhani, MA Shadbad, M Asghari Jafarabadi, N Karim Ahangar, ... International Journal of Molecular Sciences 22 (19), 10389, 2021	17	2021
A Systematic Review to Clarify the Prognostic Values of CD44 and CD44⁺CD24^- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The … M Abdoli Shadbad, N Hosseinkhani, Z Asadzadeh, A Derakhshani, ... Frontiers in Oncology 11, 689839, 2021	17	2021
Effect of superparamagnetic iron oxide nanoparticles-labeling on mouse embryonic stem cells H Parsa, K Shamsasenjan, A Movassaghpour, P Akbarzadeh, BA Tabrizi, ... Cell Journal (Yakhteh) 17 (2), 221, 2015	14	2015
COVID-19 infection: concise review based on the immunological perspective P Lotfinejad, Z Asadzadeh, S Najjary, MH Somi, K Hajiasgharzadeh, ... Immunological Investigations 51 (2), 246-265, 2022	12	2022
Tumor‐derived exosomal PD‐L1 in progression of cancer and immunotherapy SZ Rasihashemi, E Rezazadeh Gavgani, R Majidazar, P Seraji, ... Journal of Cellular Physiology 237 (3), 1648-1660, 2022	11	2022
Immunomodulatory effect of human umbilical cord blood-derived mesenchymal stem cells on activated T-lymphocyte P Lotfinejad, K Shamsasenjan, B Baradaran, E Safarzadeh, T Kazemi, ... Iranian Journal of Allergy, Asthma and Immunology 20 (6), 711-720, 2021	9	2021
The effect of bone marrow mesenchymal stem cells on the granulocytic differentiation of HL-60 cells H Nikkhah, E Safarzadeh, K Shamsasenjan, M Yousefi, P Lotfinejad, ... Turkish Journal of Hematology 35 (1), 42, 2018	7	2018
Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment SZ Rasihashemi, H Sahrai, E Rezazadeh-Gavgani, Y Yazdani, A Khalaji, ... Medical Oncology 39 (12), 183, 2022	6	2022
The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer N Dastmalchi, S Azarbarzin, R Safaralizadeh, SMB Khojasteh, ... Medical Oncology 39, 1-11, 2022	3	2022
MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel M Rasoolnezhad, R Safaralizadeh, MA Hosseinpour Feizi, ... Molecular Biology Reports 50 (10), 8407-8420, 2023	2	2023
Analyses of Kidney Biomarkers in Patients With SARS-CoV-2 (COVID-19) M Bakhshivand, F Ghorbaninezhad, T Kazemi, P Lotfinejad, V Khaze, ... Acta Medica Iranica, 168-174, 2023		2023

系统目前无法执行此操作，请稍后再试。

文章 1–20

每年引用数

重复的引用

合并的引用

添加合著者合著作者

上传 PDF

关注此作者

引用次数

合著作者

引用